Loading…
← CockpitCompetitor Analysis › TVTX Travere Therapeutics, Inc.Open in the cockpit ↗

Travere Therapeutics, Inc.TVTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling Filspari, an oral drug for IgA nephropathy, a rare progressive kidney disease.

Momentum neutral 46
Mkt cap
$4.82B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$108M
20-day average traded
Fwd P/E
17.1×
forward earnings
ROIC−WACC
-19.7 pp
WACC 10.1%
Hurdle
-3 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$50.24
1D-1.7%
1W-3.5%
1M-3.9%
3M-22.1%
6M+15.5%
YTD+31.5%
1Y+41.8%
ATR %4.8%
Beta1.25
52w lowhigh26.9% off high

What Travere Therapeutics does

Biotech selling Filspari, an oral drug for IgA nephropathy, a rare progressive kidney disease.

Sells Filspari through specialty pharmacies on prescriptions written by kidney specialists, and relies on it for growth while older rare-disease drugs such as Thiola, for the kidney-stone disorder cystinuria, give a smaller, steadier base. Formerly Retrophin, it moved Filspari from accelerated to full US approval for IgA nephropathy in 2024.

Products and services

  • Filspari (IgA nephropathy)
  • Rare kidney/metabolic pipeline

Customers

  • Nephrologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Rare kidney disease

What could go right

  • Filspari share gains as nephrologist awareness grows
  • Potential label expansion increasing addressable market

What could go wrong

  • Newer competing kidney-disease therapies from larger pharma
  • Reimbursement hurdles for a high-priced oral therapy

Moat: narrow (IP / patents, regulatory licence). One of few approved oral therapies specifically for IgA nephropathy, with orphan-drug protections.

Headquarters: San Diego, California, United States · Founded: 2003 · Employees: 497

Named competitors

Travere Therapeutics at a glance

Size Travere Therapeutics (TVTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.82B, the 1201st largest of 3,085 United States companies the cockpit tracks. Shares closed at $50.24 on 18 Nov 2026.

Performance Over six months the shares gained 15.5%, against +10.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 49.4% over the last twelve months (peer median +11.3%); the operating margin is -3.1% (peer median 19.4%).

Valuation It trades at 17.1× forward earnings against a peer median of 25.8× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 19.7 points below its cost of capital (10.1% WACC).

Credit Travere Therapeutics has 1 bond outstanding ($525M).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026TVTX 112Peer median 112
Six months, rebased to 100: Travere Therapeutics against the median of its 20 peers (local-currency closes).

Travere Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$651M$491M$233M$145M$109M
Revenue growth—+110%+61%+33%—
Gross profit$589M$420M$182M$95.3M$84.3M
EBITDA$32.4M-$2.08M-$213M-$338M-$299M
Net income-$154M-$50.3M-$322M-$337M-$278M
Free cash flow$177M$37.8M-$237M-$281M-$186M
Capital expenditure$90.9M$58.2M$36.2M$42.3M$28.6M
Total debt$616M$329M$402M$405M$407M

Quarterly statements and history in the cockpit →

Travere Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%ERASGLAXO600079EMCURE600085IPCALABPTCT326030LQDAIONS0874MANEAJANTPHARM688578600566CAMX0022946030874536TVTX6-month return →1-month return →
Up and to the right = strong over both horizons. Travere Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×GLAXO600079EMCURE600085IPCALAB326030LQDA08746885784506600566CAMX002294603087TVTXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Travere Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%GLAXO600079600085326030LQDA688578TVTXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Travere Therapeutics is the large dot.

Travere Therapeutics competitors and peer comparison

Head to head with its named competitors (TVTX vs NOVN.SW vs VERA vs VRTX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Travere Therapeutics TVTX$4.82B+16%+49%-3%17.1×17.3%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Vera Therapeutics VERA$1.85B-26%n/a-4,160%n/an/a
Vertex Pharmaceuticals VRTX$136B+25%+11%35%28.5×6.2%

How Travere Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Travere Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureTVTXPeer medianRank in peer set
1-month return-3.9%+0.2%9th lowest of 21
6-month return+15.5%+10.4%5th highest of 21
Distance from 52-week high-26.9%-27.6%11th highest of 21
Revenue growth (TTM)+49.4%+11.3%2nd highest of 19
Operating margin-3.1%19.4%2nd lowest of 19
Forward P/E17.1×25.8×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)17.3%3.4%3rd most demanding of 17
Growth delivered (Del g)+19.9%+10.9%6th highest of 17
Hurdle (Req g minus delivered)-2.5 pp-6.3 pp7th most demanding of 17
ROIC minus cost of capital-19.7 pp+5.1 pp3rd lowest of 17
Net debt / EBITDA4.5×-0.8×most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%

Travere Therapeutics bonds and credit

Travere Therapeutics has 1 bond outstanding with $525M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Travere Therapeutics's main competitors?
Named competitors: Novartis (Fabhalta) (NOVN.SW), Otsuka Pharmaceutical (private or unlisted), Calliditas Therapeutics (private or unlisted), Vera Therapeutics (VERA), Vertex Pharmaceuticals (VRTX), Dimerix (private or unlisted). The cockpit's measured peer set (industry) also includes Erasca (ERAS), GlaxoSmithKline Pharmaceuticals (GLAXO.NS), Humanwell Healthcare (Group) (600079.SS), Emcure Pharmaceuticals (EMCURE.NS), Beijing TongRenTang (600085.SS), IPCA Laboratories (IPCALAB.NS).
Is Travere Therapeutics expensive compared with its peers?
On forward p/e it trades at 17.1× against a peer median of 25.8×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Travere Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +15.5% against +10.4% for the median peer; over one year +41.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.